Long Term Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant Recipients

A Two-year Extension to a One-year, Multicenter, Partially Blinded, Double Dummy, Randomized Study to Evaluate the Efficacy and Safety of FTY720 Combined With Reduced-dose or Full-dose Cyclosporine, USP [Modified] (Novartis Brand) and Corticosteroids Versus Mycophenolate Mofetil Combined With Full-dose Cyclosporine, USP [Modified] (Novartis Brand) and Corticosteroids, in de Novo Adult Renal Transplant Recipients

This study will evaluate the long term safety and efficacy of FTY720 combined with cyclosporine and corticosteroids in patients receiving a kidney organ transplant

Inclusion Criteria

• Patients who completed the 12 month core study
• Patients who gave written informed consent to participate in the study Exclusion Criteria
• Not applicable Other protocol-defined exclusion criteria may apply